Phase 1/2 Parkinson's Disease clinical trials

15 recruiting Phase 1/2 parkinson's disease studies in the US. What trial phases mean

Other phases

RecruitingPhase 1 / Phase 2NCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Sponsor: Merck Sharp & Dohme LLC

Tucson, AZ · Los Angeles, CA · East Syracuse, NY · +2 more sites

RecruitingPhase 1 / Phase 2NCT06469944

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Sponsor: Merck Sharp & Dohme LLC

Tucson, AZ · Los Angeles, CA · Louisville, KY · +5 more sites

RecruitingPhase 1 / Phase 2NCT07863180

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

Sponsor: Prabesh Kanel

Ann Arbor, MI

RecruitingPhase 1 / Phase 2NCT07738107

ATR 1072 in Participants With PRKAG2 Syndrome

Sponsor: Atrium Therapeutics

Kansas City, MO

RecruitingPhase 1 / Phase 2NCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Sponsor: Merck Sharp & Dohme LLC

Tucson, AZ · Los Angeles, CA · Louisville, KY · +5 more sites

RecruitingPhase 1 / Phase 2NCT04165070

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Sponsor: Merck Sharp & Dohme LLC

Gilbert, AZ · Duarte, CA · San Francisco, CA · +15 more sites

RecruitingPhase 1 / Phase 2NCT03457493

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

Sponsor: University of Alabama at Birmingham

Birmingham, AL

RecruitingPhase 1 / Phase 2NCT07142044

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

Sponsor: EicOsis Human Health Inc.

Sacramento, CA

RecruitingPhase 1 / Phase 2NCT07102342

This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Sponsor: iRegene Therapeutics Co., Ltd.

New York, NY

RecruitingPhase 1 / Phase 2NCT03836950

rTMS to Improve Cognition in Parkinson's

Sponsor: VA Office of Research and Development

Chicago, IL · Hines, IL

RecruitingPhase 1 / Phase 2NCT06753331

A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

Sponsor: Sumitomo Pharma America, Inc.

Lexington, KY · New York, NY

RecruitingPhase 1 / Phase 2NCT07182058

Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

Sponsor: U: The Mind Company

Cleveland, OH

RecruitingPhase 1 / Phase 2NCT07154511

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Sponsor: Prabesh Kanel

Ann Arbor, MI

RecruitingPhase 1 / Phase 2NCT05395624

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Sponsor: Ashvattha Therapeutics, Inc.

San Francisco, CA · Stanford, CA · Jacksonville, FL

Not yet recruitingPhase 1 / Phase 2NCT07709741

Sustained Release Oral Formulation For Treatment Of Parkinsons Disease

Sponsor: University of Minnesota

Minneapolis, MN

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.